The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial

**Screening**
- Regimen A (n=160 for each regimen)
- Regimen B
- Regimen C
- Regimen D
- Regimen E

**Assignment**
- 3:1 Randomization within each Regimen

**Regimen A**
- Placebo

**Regimen B**
- Placebo

**Regimen C**
- Placebo

**Regimen D**
- Placebo

**Regimen E**
- Placebo

**Zilucoplan**
- Placebo

**Verdiperstat**
- Placebo

**CNM-Au8**
- Placebo

**Pridopidine**
- Placebo

**Trehalose**
- Placebo

**Shared Placebo**
Enrollment Updates (as of Sept 8, 2022)

- **133** individuals have signed informed consent
- **89** individuals have been randomized within Regimen E

**Thank You**

This breakthrough trial would not be possible without your participation.

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS.

Every research participant, **whether on the active drug or placebo, plays a critical role** in making the hope of finding a cure for ALS a reality.
47 Sites Currently Activated for Regimen E

(as of 9/8/22)

Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:
https://bit.ly/3r6Nd2L

ALS Link sign-up:
https://bit.ly/3o2Ds3m

Upcoming Guest Speakers:
September 15th- Tawfiq Al-Lahham, MD (Site Investigator at UPMC in PA)
September 22nd- Mariah Connolly and Meghan Hall (Site Monitors for the Platform Trial)
September 29th- Michael Elliott, MD, FAAN (Site Investigator at Swedish Medical in WA)